Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biodexa Pharmaceuticals plc - American Depositary Shares (NQ:BDRX)

6.080 +0.060 (+1.00%)
Streaming Delayed Price Updated: 1:11 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
Via ACCESS Newswire
How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market
Via ACCESS Newswire
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
Via ACCESS Newswire
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter
Via ACCESS Newswire
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
Via ACCESSWIRE
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition
Via ACCESSWIRE
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
Via ACCESSWIRE
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
Via ACCESS Newswire
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
Via ACCESSWIRE
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
Via ACCESSWIRE
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Via ACCESSWIRE
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data
Via ACCESSWIRE
Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer
Via ACCESSWIRE
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Via ACCESSWIRE
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Via ACCESSWIRE
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Via ACCESSWIRE
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
Via ACCESSWIRE
Biodexa Pharmaceuticals PLC Announces Issue of Pre-Funded Warrants
Via ACCESSWIRE
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
Via ACCESSWIRE
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
Via ACCESSWIRE
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.